Physician profile
Paramvir S Rahal
NPI 1003893223
$4,024.19
in general payments reported to CMS, 2019-2025
25 companies · $614 in 2025
The $614 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $316 · 2021: $546 · 2022: $890 · 2023: $481 · 2024: $859 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $964.68 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $685.89 | 2024-2025 | Vowst, Zenpep |
| Celgene Corporation | $306.53 | 2022-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $274.39 | 2021-2023 | |
| Gilead Sciences, INC. | $266.81 | 2019-2025 | |
| Janssen Biotech, INC. | $205.17 | 2019-2024 | Stelara |
| Ardelyx, INC. | $201.72 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $194.57 | 2019-2024 | Xifaxan |
| Daiichi Sankyo INC. | $134.64 | 2019-2023 | Injectafer |
| Redhill Biopharma INC. | $115.56 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $111.63 | 2021-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $89.66 | 2019-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $81.94 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.20 | 2019-2025 | Eohilia |
| Pfizer INC. | $58.88 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $35.78 | 2023-2024 | Voquezna |
| Capsovision, INC. | $33.19 | 2023-2024 | Capsocam Plus |
| Smith+Nephew, INC. | $31.51 | 2025 | Collagenase Santyl |
| Ipsen Biopharmaceuticals, INC | $30.71 | 2025 | Iqirvo |
| Shionogi INC | $30.47 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $24.88 | 2020 | |
| Madrigal Pharmaceuticals | $21.34 | 2024 | Resmetirom |
| Echosens North America, INC. | $21.25 | 2021-2025 | Fibroscan |
| Albireo Pharma, INC. | $20.73 | 2024 | Bylvay |
| Ethicon US, LLC | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paramvir Rahal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.